111YI +4.74%55 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus rates YI with a GF Score™ of 55/100 and a GF Value™ of $6.65 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 69 Medical Distribution companies, 111 ranks worse than 1449273.91% on this metric.
111's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for 111's 5-Year Yield-on-Cost % or its related term are showing as below:
YI's 5-Year Yield-on-Cost % is not ranked *
in the Medical Distribution industry.
Industry Median: 3.25 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
111 (NAS:YI) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
111 5-Year Yield-on-Cost % Related Terms
YI vs COSM, HKPD, SNYR: 5-Year Yield-on-Cost % Comparison
For the Medical Distribution subindustry, 111's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
111 5-Year Yield-on-Cost % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, 111's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where 111's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
111 (YI) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 11, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on 111 and its competitors. According to the industry distribution chart, 111 ranks #999999 out of 69 companies in the Medical Distribution industry.
Is 111's 5-Year Yield-on-Cost % too high?
111's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, 111 ranks #999999 out of 69 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, 111 has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 111's 5-Year Yield-on-Cost % compare to COSM and HKPD?
According to the Medical Distribution industry distribution chart, 111 ranks #999999 out of 69 companies for 5-Year Yield-on-Cost %. This places 111 in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 3.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Distribution company?
The median 5-Year Yield-on-Cost % among Medical Distribution companies is 3.25, based on 69 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on 111 and its competitors. For the Medical Distribution industry, the median 5-Year Yield-on-Cost % is 3.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 111's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 111 stock overvalued right now?
Based on GuruFocus' analysis, 111 (YI) is currently considered Possible Value Trap. The stock's GF Value™ is $6.65, compared to a current price of $4.20 — trading 36.8% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. 111's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For 111 (YI), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 111 (YI) Overvalued in 2026?
Based on GuruFocus' analysis, 111 stock appears to be undervalued.
The current stock price of $4.20 is trading 36.8% below its estimated GF Value™ of $6.65.
GuruFocus considers 111 to be Possible Value Trap.
Key valuation signals for YI:
5-Year Yield-on-Cost %: 0.00
GF Value™: $6.65 vs. price of $4.20 (36.8% below fair value)
No single metric tells the full story. See the YI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
55GF Score
Get the complete analysis for YI
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YI has been successfully added to your 